Blueprint Medicines Corp is a biopharmaceutical company that focuses on delivering transformative therapies for patients. The company is driven by a clear set of values and corporate philosophy. Blueprint Medicines Corp stands for innovation, collaboration, and a strong commitment to patients and their families. With a team of dedicated professionals, the company strives to make a meaningful impact on patients' lives by advancing precision medicine. By leveraging their expertise in genomics, Blueprint Medicines Corp aims to develop highly selective medicines to target genetic drivers of disease. Through their relentless pursuit of excellence, the company seeks to redefine the treatment landscape and provide hope for patients in need.

Blueprint Medicines Corp is primarily present in the United States.

Blueprint Medicines Corp has achieved several significant milestones. The company received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2020 for its drug, Ayvakit, to treat certain types of advanced gastrointestinal stromal tumors (GIST). In the same year, Blueprint Medicines Corp also obtained FDA approval for its drug, Gavreto, to treat metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer. These approvals signify the company's progress in developing targeted therapies for oncology patients. Additionally, Blueprint Medicines Corp has collaborated with various pharmaceutical companies to expand its research and development efforts, further establishing itself as a leader in precision medicine.

Blueprint Medicines Corp is a leading biopharmaceutical company that focuses on developing highly targeted therapies for genomically defined diseases. Founded in 2008, Blueprint Medicines Corp has a rich history in precision medicine, utilizing a deep understanding of genomics to identify and address the underlying genetic drivers of various diseases. The company has built a strong portfolio of investigational drugs that target specific genetic abnormalities, with a particular emphasis on cancers, rare diseases, and immunological disorders. Through its innovative approach, Blueprint Medicines Corp aims to bring transformative treatments to patients in need, driving advancements in personalized medicine and improving clinical outcomes.

The main competitors of Blueprint Medicines Corp in the market include companies such as Amgen, Novartis, and Pfizer.

Blueprint Medicines Corp is primarily active in the biotechnology and pharmaceutical industries.

Blueprint Medicines Corp's business model revolves around developing targeted therapies for genetically defined diseases. The company focuses on precision medicines that target the root cause of diseases at a molecular level. Blueprint Medicines combines deep understanding of disease biology with advanced scientific techniques to identify and develop therapeutics that address unmet medical needs. By leveraging their proprietary research platform and strong scientific expertise, the company aims to discover and advance multiple drug candidates, ultimately delivering transformative treatments to patients. Blueprint Medicines Corp's business model prioritizes innovation, scientific rigor, and strategic partnerships to improve patient outcomes in areas such as oncology and rare genetic disorders.

P/E odnos Blueprint Medicines iznosi -62,73.

KUV kompanije Blueprint Medicines iznosi 10,31.

AlleAktien kvalitativni skor za Blueprint Medicines je 3/10.

očekivana Blueprint Medicines promet je 504,99 mil. USD.

Dobit očekivana Blueprint Medicines je -83,02 mil. USD.

Blueprint Medicines Corp is a biopharmaceutical company specializing in the development of precision medicine for cancer and rare diseases. The company uses a proprietary platform for the discovery and development of kinase inhibitors to identify potential clinical candidates for personalized treatment. The business model of Blueprint Medicines is focused on three main areas: research and development, product commercialization, and partnerships. Research and development is at the core of the business model as the company focuses on developing drugs for indications where existing treatment options are inadequate or nonexistent. The company has a range of products in various stages of clinical development, including Avapritinib, Pralsetinib, AYVAKIT, and GZ/SAR439859. Avapritinib is a kinase inhibitor being developed for the treatment of gastrointestinal stromal tumors and systemic mastocytosis. Pralsetinib is an oral selective RET inhibitor being developed for the treatment of patients with RET-altered thyroid cancer and non-small cell lung cancer. AYVAKIT is a selective inhibitor of KIT and PDGFRA being developed for the treatment of patients with advanced basal cell carcinoma with KIT and PDGFRA mutations. GZ/SAR439859 is a selective BRAF inhibitor being developed for the treatment of patients with advanced melanoma and other solid tumors. Blueprint Medicines also operates a product commercialization division focused on the marketing and sale of already approved products and products in advanced stages of development. The company has an internal sales team responsible for marketing its products in the United States and also works with partners to sell its products internationally. Partnerships also play a key role in Blueprint Medicines' business model. The company has formed strategic partnerships with leading pharmaceutical and biotechnology companies such as Roche, CStone Pharmaceuticals, and Alexandria Real Estate Equities. These partnerships support the company's commitment to the development of precision medicine and provide access to resources and technologies to further expand its product portfolio. Overall, Blueprint Medicines' business model is focused on the development and commercialization of drugs for the treatment of cancer and rare diseases. The company pursues a comprehensive research and development strategy to identify potential clinical candidates and has a product pipeline focused on various indications. It also operates a product commercialization division and collaborates with leading pharmaceutical and biotechnology companies to build partnerships and sell products internationally.

Blueprint Medicines isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Blueprint Medicines trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Blueprint Medicines je US09627Y1091.

WKN od Blueprint Medicines je A14SDD.

Oznaka za praćenje akcija kompanije Blueprint Medicines je BPMC.

U poslednjih 12 meseci, Blueprint Medicines je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Blueprint Medicines će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Blueprint Medicines trenutno iznosi .

Blueprint Medicines isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Blueprint Medicines je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Blueprint Medicines se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Blueprint Medicines od 22. 10. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 22. 10. 2024..

Isplata poslednje dividende izvršena je 22. 10. 2024..

U godini 2023 kompanija Blueprint Medicines je isplatila 0 USD kao dividende.

Dividende od Blueprint Medicines se isplaćuju u USD.